AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33374791 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol oral gel 0.05%
Number of subjects: 40
Study 33374791 — intervention group
Group type: COMPARATOR
Intervention: Anti-inflammatory mouthwash (calcium hydroxide, hyaluronic acid, umbelliferone, oligomeric pro-anthocyanidins)
Number of subjects: 40
Study 35419166 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill exercise three times/week for three months with MIND diet
Number of subjects: 68
Study 35419166 — intervention group
Group type: COMPARATOR
Intervention: MIND diet only
Number of subjects: 68
Study 34603442 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenous before skin incision
Number of subjects: 47
Study 34603442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 34894273 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Patient Management (RPM)
Number of subjects: 1538
Study 34894273 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1538
Study 32075228 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol® 50 mg
Number of subjects: 25
Study 32075228 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol® 400 mg
Number of subjects: 25
Study 36760029 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue expander used in a separate surgery before bone grafting surgery
Number of subjects: 16
Study 36760029 — intervention group
Group type: COMPARATOR
Intervention: Control group received treatment including single surgery of bone grafting associated with periosteal releasing incision
Number of subjects: 16
Study 34313093 — intervention group
Group type: EXPERIMENTAL
Intervention: Critically important antimicrobials administered sub-therapeutically for prophylaxis and growth enhancement purposes.
Number of subjects: 2402
Study 33238999 — intervention group
Group type: EXPERIMENTAL
Intervention: ISTp-DP
Number of subjects: 777
Study 33238999 — intervention group
Group type: COMPARATOR
Intervention: IPTp-SP
Number of subjects: 777
Study 35147813 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 17
Study 35147813 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 17
Study 33710263 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (HT) including conjugated equine estrogens (E) alone for women without a uterus (n=560) and E plus medroxyprogesterone acetate (P) for those with an intact uterus (n=610)
Number of subjects: 1170
Study 33710263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1170
Study 35577478 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue DMARD therapy after first dose vaccination
Number of subjects: 181
Study 35577478 — intervention group
Group type: EXPERIMENTAL
Intervention: Withhold DMARD therapy after first dose vaccination
Number of subjects: 181
Study 35577478 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue DMARD therapy after second dose vaccination
Number of subjects: 181
Study 35577478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DMARD therapy)
Number of subjects: 181
Study 35577478 — intervention group
Group type: EXPERIMENTAL
Intervention: tsDMARD therapy
Number of subjects: 181
Study 33974920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-workout supplement (SUPP)
Number of subjects: 10
Study 33974920 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 32910107 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 33
Study 32910107 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulation-based training)
Number of subjects: 33
Study 36477362 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential belimumab + rituximab
Number of subjects: 86
Study 36477362 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study 36477362 — intervention group
Group type: COMPARATOR
Intervention: belimumab
Number of subjects: 86
Study 36477362 — intervention group
Group type: COMPARATOR
Intervention: rituximab
Number of subjects: 86
Study 34195880 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted high fat mass
Number of subjects: 0
Study 34195880 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted high fat-free mass
Number of subjects: 0
Study 34195880 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted fat mass, fat-free mass, and fat percentage
Number of subjects: 0
Study 34195880 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted fat-free mass
Number of subjects: 0
Study 35960482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 4313
Study 35960482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 4313
Study 35960482 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NSAIDs
Number of subjects: 4313
Study 35960482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4313
Study 33232811 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP only (Arm A)
Number of subjects: 0
Study 33232811 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP and shock (Arm B)
Number of subjects: 0
Study 33232811 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock only (Arm C)
Number of subjects: 0
Study 33232811 — intervention group
Group type: COMPARATOR
Intervention: Arm A vs Arm B
Number of subjects: 0
Study 33232811 — intervention group
Group type: COMPARATOR
Intervention: Arm A vs Arm C
Number of subjects: 0
Study 32716115 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-use LED mask device and HA ampoule (Group A)
Number of subjects: 48
Study 32716115 — intervention group
Group type: COMPARATOR
Intervention: HA ampoule only (Group B)
Number of subjects: 48
Study 33908610 — intervention group
Group type: EXPERIMENTAL
Intervention: CARBO/ETO + HDCT
Number of subjects: 35
Study 33908610 — intervention group
Group type: COMPARATOR
Intervention: Other treatments
Number of subjects: 35
Study 33908610 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized disease (M0) with no residual tumor
Number of subjects: 35
Study 33908610 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized disease (M0) with residual tumor
Number of subjects: 35
Study 33908610 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratentorial location
Number of subjects: 35
Study 33599777 — intervention group
Group type: EXPERIMENTAL
Intervention: High smoking motivation condition (nicotine-deprived and/or smoking cue exposure)
Number of subjects: 90
Study 33599777 — intervention group
Group type: COMPARATOR
Intervention: Low smoking motivation condition (non-deprived and/or control cue exposure)
Number of subjects: 90
Study 33599777 — intervention group
Group type: EXPERIMENTAL
Intervention: High smoking motivation condition
Number of subjects: 90
Study 33599777 — intervention group
Group type: COMPARATOR
Intervention: Low smoking motivation condition
Number of subjects: 90
Study 33599777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 90
Study 33150744 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW social status condition
Number of subjects: 133
Study 33150744 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 133
Study 35524760 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast nurse intervention including education, literacy material, empathetic counselling, phone call reminders, and monitoring of medication refill.
Number of subjects: 162
Study 35524760 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast nurse intervention.
Number of subjects: 162
Study 35524760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breast nurse intervention).
Number of subjects: 162
Study 34521217 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management (medical therapy + angiography and revascularization if feasible)
Number of subjects: 2553
Study 34521217 — intervention group
Group type: COMPARATOR
Intervention: Conservative approach (medical therapy alone with revascularization if medical therapy failed)
Number of subjects: 2553
Study 34521217 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 2553
Study 34521217 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetes
Number of subjects: 2553
Study 34521217 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin-treated diabetes
Number of subjects: 2553
Study 34521217 — intervention group
Group type: COMPARATOR
Intervention: Invasive management vs conservative approach
Number of subjects: 2553
Study 35016887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Nivolumab
Number of subjects: 16
Study 35016887 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 16
Study 32579120 — intervention group
Group type: EXPERIMENTAL
Intervention: MyIDEA educational app intervention
Number of subjects: 45
Study 32579120 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 45
Study 34974019 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor dehumidification (reduced relative humidity from 75% to 45%)
Number of subjects: 36
Study 33736740 — intervention group
Group type: EXPERIMENTAL
Intervention: TGT-SN
Number of subjects: 404
Study 33736740 — intervention group
Group type: EXPERIMENTAL
Intervention: TGT-only
Number of subjects: 404
Study 33736740 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 404
Study 33671493 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing high sn-2 palmitate (sn-2 group, n = 66)
Number of subjects: 199
Study 33671493 — intervention group
Group type: COMPARATOR
Intervention: Formula containing low sn-2 palmitate (control group, n = 67)
Number of subjects: 199
Study 33671493 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed group (BF group)
Number of subjects: 199
Study 35661659 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 40
Study 32986682 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06412562 (split dose 25+20mg)
Number of subjects: 6
Study 32986682 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) carbidopa/levodopa
Number of subjects: 6
Study 36368945 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU cholecalciferol 2wks-1
Number of subjects: 56
Study 36368945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 32667582 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course hyperthermic intraperitoneal chemotherapy (HIPEC) for 30 minutes
Number of subjects: 15
Study 35272263 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 368
Study 35272263 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting PA guidelines
Number of subjects: 368
Study 35272263 — intervention group
Group type: COMPARATOR
Intervention: Not married
Number of subjects: 368
Study 35272263 — intervention group
Group type: COMPARATOR
Intervention: Living alone
Number of subjects: 368
Study 33507877 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning course with video examples
Number of subjects: 145
Study 33507877 — intervention group
Group type: COMPARATOR
Intervention: attendance course with role-playing
Number of subjects: 145
Study 33781259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy including six levels of rehabilitation exercises
Number of subjects: 80
Study 33781259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 80
Study 33263702 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte 148
Number of subjects: 0
Study 33263702 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 0
Study 33263702 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion speed (333mL/h)
Number of subjects: 0
Study 33263702 — intervention group
Group type: COMPARATOR
Intervention: Rapid infusion speed (999mL/h)
Number of subjects: 0
Study 35734048 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation extracapsular tonsillectomy
Number of subjects: 293
Study 35734048 — intervention group
Group type: COMPARATOR
Intervention: Monopolar extracapsular tonsillectomy
Number of subjects: 293
Study 35734048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 293
Study 32612104 — intervention group
Group type: EXPERIMENTAL
Intervention: mERAS protocol
Number of subjects: 104
Study 32612104 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 33506955 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 63
Study 33506955 — intervention group
Group type: COMPARATOR
Intervention: FVIII prophylaxis
Number of subjects: 63
Study 32458506 — intervention group
Group type: EXPERIMENTAL
Intervention: Home collection of semen samples
Number of subjects: 110
Study 32458506 — intervention group
Group type: COMPARATOR
Intervention: Clinic collection of semen samples
Number of subjects: 110
Study 616026133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dk contact lens (Dk=28)
Number of subjects: 10
Study 616026133 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dk contact lens (Dk=110)
Number of subjects: 10
Study 35340225 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with aerobic exercise
Number of subjects: 60
Study 35340225 — intervention group
Group type: COMPARATOR
Intervention: Exercise prescription (Control)
Number of subjects: 60
Study 34387408 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/d
Number of subjects: 102
Study 34387408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 33280783 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 64
Study 33280783 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 35713670 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (Tα1) 1.6 mg every 12 hours for the first 7 days and 1.6 mg once a day for the subsequent 7 days
Number of subjects: 508
Study 35713670 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 508
Study 34823120 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGlated nanoliposome of pistachio unsaturated oils (PEGNLPUOs)
Number of subjects: 0
Study 34823120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32462427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous autologous bone marrow-derived MSCs
Number of subjects: 31
Study 32462427 — intervention group
Group type: COMPARATOR
Intervention: Control (no MSC treatment)
Number of subjects: 31
Study 33545758 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 agents
Number of subjects: 3
Study 34549251 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 14
Study 34549251 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training
Number of subjects: 14
Study 34549251 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 14
Study 36448721 — intervention group
Group type: EXPERIMENTAL
Intervention: IPACK block added to ACB and PAI
Number of subjects: 89
Study 36448721 — intervention group
Group type: COMPARATOR
Intervention: ACB and PAI only (control group)
Number of subjects: 89
Study 33647042 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte subtypes (classical, intermediate, non-classical) and total monocyte count
Number of subjects: 690
Study 32077134 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS home sampling
Number of subjects: 48
Study 32077134 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48
Study 36477478 — intervention group
Group type: EXPERIMENTAL
Intervention: RHEpo (3000 IU/kg)
Number of subjects: 448
Study 36477478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 0.9%)
Number of subjects: 448
Study 33755088 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure (LP: 7 mmHg)
Number of subjects: 127
Study 33755088 — intervention group
Group type: COMPARATOR
Intervention: Standard pressure (SP: 12 mmHg)
Number of subjects: 127
Study 33432852 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective and therapeutic exercises over 12 weeks
Number of subjects: 0
Study 33432852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 0
Study 34329774 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmetirom 80 mg daily
Number of subjects: 125
Study 34329774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 34402728 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg drospirenone (DRSP)
Number of subjects: 858
Study 34402728 — intervention group
Group type: COMPARATOR
Intervention: 0.075 mg desogestrel (DSG)
Number of subjects: 858
Study 32096667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia-Normoxia (IHN)
Number of subjects: 21
Study 32096667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia-Hyperoxia (IHH)
Number of subjects: 21
Study 32096667 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IHN and IHH
Number of subjects: 21
Study 34908160 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interactions (PCI) intervention
Number of subjects: 170
Study 34908160 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 170
Study 32485633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (16 sessions of 30 minutes, twice a week for 8 weeks)
Number of subjects: 33
Study 32485633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hippotherapy)
Number of subjects: 33
Study 35115352 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (fistula creation)
Number of subjects: 195
Study 35115352 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft placement (intervention arm)
Number of subjects: 195
Study 35115352 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter insertion (intervention arm)
Number of subjects: 195
Study 33710815 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1101
Number of subjects: 535
Study 33710815 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 535
Study 32392952 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surfactant administration (MISA)
Number of subjects: 92
Study 32392952 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation surfactant administration (EISA)
Number of subjects: 92
Study 34615565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity-Interval-Training (HIIT)
Number of subjects: 51
Study 34615565 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic-Endurance Exercise (AE)
Number of subjects: 51
Study 34615565 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 51
Study 34562262 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus background regimen (isoniazid, rifampin, pyrazinamide, ethambutol)
Number of subjects: 1151
Study 34562262 — intervention group
Group type: COMPARATOR
Intervention: Control group (background regimen of isoniazid, rifampin, pyrazinamide, ethambutol)
Number of subjects: 1151
Study 33596857 — intervention group
Group type: EXPERIMENTAL
Intervention: Infographic designed by the Behavioural Insights Team (BIT)
Number of subjects: 4099
Study 33596857 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli from WHO
Number of subjects: 4099
Study 32187462 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (284 mg) administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter for 540 days
Number of subjects: 3178
Study 32187462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3178
Study 32187462 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (284 mg)
Number of subjects: 3178
Study 35045168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 291
Study 35045168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 33164983 — intervention group
Group type: COMPARATOR
Intervention: 40% pre-ASiR-V, 70% post-ASiR-V (Group A)
Number of subjects: 150
Study 33164983 — intervention group
Group type: COMPARATOR
Intervention: 50% pre-ASiR-V, 70% post-ASiR-V (Group B)
Number of subjects: 150
Study 33164983 — intervention group
Group type: COMPARATOR
Intervention: 60% pre-ASiR-V, 70% post-ASiR-V (Group C)
Number of subjects: 150
Study 33164983 — intervention group
Group type: COMPARATOR
Intervention: 70% pre-ASiR-V, 70% post-ASiR-V (Group D)
Number of subjects: 150
Study 33164983 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% post-ASiR-V (D4 subgroup)
Number of subjects: 150
Study 33164983 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% post-ASiR-V (D5 subgroup)
Number of subjects: 150
Study 33164983 — intervention group
Group type: EXPERIMENTAL
Intervention: 40%-90% post-ASiR-V (D0-D5 subgroups)
Number of subjects: 150
Study 34328476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 20
Study 34328476 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement
Number of subjects: 20
Study 35039439 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 0.4 mL/kg of 0.25% ropivacaine
Number of subjects: 60
Study 35039439 — intervention group
Group type: EXPERIMENTAL
Intervention: II/IH block with 0.2 mL/kg of 0.25% ropivacaine
Number of subjects: 60
Study 35039439 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB with 0.4 mL/kg of 0.25% ropivacaine
Number of subjects: 60
Study 35039439 — intervention group
Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 60
Study 35039439 — intervention group
Group type: COMPARATOR
Intervention: II/IH block
Number of subjects: 60
Study 35039439 — intervention group
Group type: COMPARATOR
Intervention: QLB
Number of subjects: 60
Study 33947344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 mcg/kg/day for 5 days added to hydroxychloroquine + favipiravir + azithromycin
Number of subjects: 66
Study 33947344 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment (hydroxychloroquine + favipiravir + azithromycin) without ivermectin
Number of subjects: 66
Study 33947344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 66